Characterization of a Dual CDC7/CDK9 Inhibitor in Multiple Myeloma Cellular Models

Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer m...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2013-07, Vol.5 (3), p.901-918
Main Authors: Natoni, Alessandro, Coyne, Mark R E, Jacobsen, Alan, Rainey, Michael D, O'Brien, Gemma, Healy, Sandra, Montagnoli, Alessia, Moll, Jürgen, O'Dwyer, Michael, Santocanale, Corrado
Format: Article
Language:English
Subjects:
Apoptosis
Cell cycle
Chemotherapy
Inhibitor drugs
Multiple myeloma
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two key features of myeloma cells are the deregulation of the cell cycle and the dependency on the expression of the BCL2 family of anti-apoptotic proteins. The cell division cycle 7 (CDC7) is an essential S-phase kinase and emerging CDC7 inhibitors are effective in a variety of preclinical cancer models. These compounds also inhibit CDK9 which is relevant for MCL-1 expression. The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers5030901